Literature DB >> 10226533

Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.

M Kornmann1, J Kleeff, W Debinski, M Korc.   

Abstract

BACKGROUND: Interleukin (IL)-13 and -4 are multifunctional cytokines that bind to specific cell-surface receptors. The aim of this study was to determine whether pancreatic cancer cells express either receptor, and to assess the growth suppressive effects of chimeric proteins composed of a Pseudomonas exotoxin (PE) A mutant (PE38QQR) fused to IL-13 (IL-13-PE38QQR) or IL-4 (IL-4-PE38QQR) in these cells.
MATERIALS AND METHODS: Northern and Western blot analysis were used to analyze the expression of IL-4/-13 receptors and the common gamma chain (gamma c) in pancreatic cancer cell lines. MTT growth assays were carried out to assess the effects of IL-4/-13 and IL-4/-13-PE38QQR on cell growth.
RESULTS: All 6 pancreatic cancer cell lines examined expressed IL-13R alpha 1 and IL-4R alpha, one cell line expressed IL-13R alpha 2, and 5 pancreatic cancer cell lines expressed gamma c. IL-13 (5 nM) significantly enhanced the growth of 3 cell lines, whereas IL-4 (5 nM) enhanced the growth of 1 cell line. In contrast, IL-13-PE38QQR and IL-4-PE38QQR inhibited the growth of all 6 tested cell lines. There were large variations in the individual sensitivity of the cells, with LD50 values ranging from 100 ng/ml to 5 micrograms/ml for IL-13-PE38QQR and from 20 ng/ml to 10 micrograms/ml for IL-4-PE38QQR. IL-13 and -4 antagonized these inhibitory activities in some, but not all, of the cell lines.
CONCLUSIONS: IL-13 and -4 may act as mitogens toward pancreatic cancer cells by activating IL-4- and IL-13-receptors and IL-13- and IL-4-coupled toxins may ultimately have a role in the treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226533

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.435


  16 in total

1.  An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.

Authors:  Hetal Pandya; Denise M Gibo; Shivank Garg; Steven Kridel; Waldemar Debinski
Journal:  Neuro Oncol       Date:  2011-09-26       Impact factor: 12.300

2.  Novel Molecular Multilevel Targeted Antitumor Agents.

Authors:  Poonam Sonawane; Young A Choi; Hetal Pandya; Denise M Herpai; Izabela Fokt; Waldemar Priebe; Waldemar Debinski
Journal:  Cancer Transl Med       Date:  2017-06-08

3.  A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.

Authors:  Seunguk Oh; Brad J Stish; Selwyn M Vickers; Donald J Buchsbaum; Ashok K Saluja; Daniel A Vallera
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 4.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

5.  A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.

Authors:  Seunguk Oh; Deborah A Todhunter; Angela Panoskaltsis-Mortari; Donald J Buchsbaum; Shoko Toma; Daniel A Vallera
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

Review 6.  Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.

Authors:  Alessandro Paniccia; Justin Merkow; Barish H Edil; Yuwen Zhu
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

7.  Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.

Authors:  D A Vallera; B J Stish; Y Shu; H Chen; A Saluja; D J Buchsbaum; S M Vickers
Journal:  Gut       Date:  2008-01-25       Impact factor: 23.059

8.  Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases.

Authors:  Andrea Formentini; Olga Prokopchuk; Joern Sträter; Joerg Kleeff; Lukasz Filip Grochola; Gerd Leder; Doris Henne-Bruns; Murray Korc; Marko Kornmann
Journal:  Int J Colorectal Dis       Date:  2008-08-31       Impact factor: 2.571

9.  Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions.

Authors:  O Prokopchuk; Y Liu; D Henne-Bruns; M Kornmann
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

10.  Modulation of Cytokines Production by Indomethacin Acute Dose during the Evolution of Ehrlich Ascites Tumor in Mice.

Authors:  Luciana Boffoni Gentile; Nicolle Queiroz-Hazarbassanov; Cristina de Oliveira Massoco; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2015-08-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.